







▲ My GenomeWeb

Business & Policy Technology Research

Diagnostics Disease Areas

Applied Markets

Resources

Enter your keywords

Home » Business, Policy & Funding » Business News

Viome Raises \$54M to Advance mRNA Platform for Diagnosis, Drug Development

Nov 10, 2021 | staff reporter

Save for later

NEW YORK - Viome Life Sciences said Wednesday that it has raised \$54 million in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over \$125 million in total.

This latest influx will support expanded clinical research focused on aggressive cancers and chronic diseases, with an eventual goal of developing early-stage diagnostics and therapeutics using the firm's mRNA platform. Initially focused on direct-to-consumer, gut microbiome-based wellness testing, Viome has more recently expanded its ambitions to these broader areas.

Cancers in which the firm is researching its technology include pancreatic cancer, bile cancer, breast cancer, gastrointestinal cancers, gynecological cancers, and head, neck, and shoulder cancers. The company said it also has active therapeutics efforts in Alzheimer's, metabolic diseases, and mental health.

Viome and GlaxoSmithKline recently announced an agreement to expand a clinical validation partnership to develop new therapeutic interventions for select cancers and autoimmune diseases.

Returning investors in the pre-series C financing included Khosla Ventures, West River Group, Glico, Physician Partners, and Bold Capital Group. Ocgrow Ventures also participated as a new investor, and Viome said Harish Consul, Ocgrow's founder and CEO, will consequently serve as an observer on its board of directors.



We recommend

Startup Viome Raises \$15M in Series A Funding

GenomeWeb, 2017

'Fun, But'

GenomeWeb, 2017

Viome Forays Outside Molecularly Informed DTC Wellness Testing With Oral Cancer Assay | Genomeweb

Molika Ashford, GenomeWeb

Viome, Helomics Form Microbiome Analysis Partnership

staff reporter, GenomeWeb, 2019

Viome Shares First Details of DTC Microbiome Technology as Research Community Weighs Evidence

GenomeWeb, 2019

Startup Viome Raises \$15M in Series A Funding | Genomeweb

staff reporter, GenomeWeb

In Brief This Week: Ginkgo Bioworks, Novacyt, Viome, and More | Genomeweb

staff reporter, GenomeWeb

Viome Forays Outside Molecularly Informed DTC Wellness Testing With Oral Cancer Assay

Molika Ashford, GenomeWeb, 2021

Powered by TREND MD

Breaking News O Quantum-Si Posts No Revenues in Q3 as Net Loss Doubles Cue Health Revenues up Massively in Q3 23andMe Fiscal Q2 Revenues Increase 7 Percent Israeli Government Extends CRISPR-IL Consortium With \$14.5M in New Funding

HHS Provides \$650M to Support Point-


Isoplexis Q3 Revenues Grow 28 Percent


of-Care MDx Tests for COVID-19


SCAN

Who Did What

What's Popular? Color Health Raises \$100M in Series E Round. Plans to Expand Healthcare Services Oncology Opportunities Provide 'Pot of Gold at the End of the Double Rainbow' for Illumina 🐇 3 Invitae Unveils Plans to







Genome Biology Papers on RNA Sequence Variants, Sequencing Quality Control 2, Walnut

In Genome Biology this week: pipeline to uncover RNA sequence variants, insights from the SEQC2 project, and more.

Adaptation

About us Advertise Contact FAQ Jobs Sitemap Submit a Tip